Loading...
Efavirenz — Export Intelligence Report
2025-Q4 · TransData Nexus
PHARMA TRADE INTELLIGENCE
INDIA EXPORT INTELLIGENCE REPORT
Efavirenz
2025-Q4
Comprehensive analysis of India’s efavirenz export trade — suppliers, buyers, prices, routes, and every shipment record.
47
Shipments
$1.37M
Trade Value
10
Suppliers
23
Buyers
18
Countries
Scan for online report
Talk to our analyst: +91 95950 78788
https://transdatanexus.com/pharmaceutical/efavirenz
01
PART I — OVERVIEW
Executive Summary
At-a-glance KPIs, key findings, and strategic positioning of India’s efavirenz trade — 2025-Q4
KEY TAKEAWAY
Efavirenz 2025-Q4 exports total $1.4M across 18 countries, with MACLEODS PHARMACEUTICALS LTD commanding 39.6% market share.
TOTAL SHIPMENTS
47
2025-Q4
EXPORT VALUE
$1.4M
FOB USD
TOTAL QUANTITY
8.1M
units shipped
INDIAN SUPPLIERS
10
unique exporters
GLOBAL BUYERS
23
unique importers
DESTINATIONS
18
countries
MEDIAN UNIT PRICE
$0.375
per unit
TOP-5 SHARE
99.2%
of total USD
BRANDED SHARE
53.2%
25 shipments
DOSAGE FORMS
3
product types
6 KEY FINDINGS
1
MACLEODS PHARMACEUTICALS LTD is India's #1 Efavirenz exporter with $542.4K (39.6% market share).→ §5, Indian Supplier Rankings
2
Efavirenz reached 18 countries, with Algeria as the top destination ($390.3K).→ §4, Global Destination Map
3
Market concentration is high (HHI: 2902) — top 10 suppliers control 100.0% of exports.→ §5, Indian Supplier Rankings
4
95.7% of buyers (22 of 23) source from a single Indian supplier — potential poaching opportunities.→ §6, Global Buyer Rankings
5
Tablet dominates (70.1%) across 3 dosage forms.→ §7, Price Benchmarks
6
18 countries have ≤5 Indian suppliers — easy-entry markets for SME exporters.→ §9, Strategic Opportunities
WHO THIS REPORT IS FOR
S SUPPLIERS (Indian pharma exporters)
- See which buyers your competitors are shipping to, at what price, through which ports
- Identify buyers that are single-sourced (poaching opportunities)
- Benchmark your pricing and catalog vs the Top 25
B BUYERS (global importers)
- Discover which Indian exporters supply this product and what they sell
- Benchmark the price you are paying vs the market median by country and dosage
- Identify alternative suppliers with proven exports to similar destinations
Figure 1.1 MACLEODS PHARMACEUTICALS LTD leads in volume — how do 10 exporters compare on price × volume?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Every bubble is one Indian efavirenz exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Efavirenz report covers
KEY TAKEAWAY
Every figure in this report is grounded in real commercial efavirenz trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian efavirenz suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Efavirenz India trade report
Product scope
Efavirenz
All variants merged — branded and generic formulations of efavirenz
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
Shipments analysed
47
Every commercial efavirenz trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
DATA ACCURACY
99.9%
Validation rate on core fields — supplier, buyer, product, quantity, value.
UPDATE FREQUENCY
Daily
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
- Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
- This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
- A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
- This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY
2025-Q4 followed a steady rise: Oct $106.6K, Nov $468.3K, Dec $793.2K. Shipment counts rose across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$106.6K
Oct USD
1 shipments
2
$468.3K
Nov USD
+339.3% MoM
3
$793.2K
Dec USD
+69.4% MoM
4
Steady rise
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov rose 339.3% in USD but shipment count kept climbing.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $107K, making it the weakest month by value.
Fig 3.2 Q4 cumulative USD reached $1.4M.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
Fig 3.3 $362K rise in Nov, $325K recovery in Dec.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = absolute monthly value. Red = month-over-month loss; green = gain. Insight: Trade grew steadily across the quarter.
Fig 3.4 Regional breakdown by month — which corridors swung most?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
§3.1 Monthly summary
| Oct | $107K | 1 shipments |
| Nov | $468K | 17 shipments |
| Dec | $793K | 29 shipments |
| Q4 Total | $1.4M | 47 shipments |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 3.5 Top 10 destination countries by monthly USD rank — who’s rising?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a country’s monthly rank. Lines crossing = rank swaps. Insight: United States held #1 throughout the quarter.
Fig 3.6 Top 10 Indian exporters by monthly USD rank.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: MACLEODS PHARMACEUTICALS LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import efavirenz from India, how much they buy, and who supplies each market
KEY TAKEAWAY
Algeria absorbs 28.5% of India’s 2025-Q4 efavirenz trade ($390.3K). Beyond the top 10 destinations, 18 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Africa has 7 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 18 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much efavirenz India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$462K
33.8% of trade
7 countries · 15 shipments
Americas
$428K
31.3% of trade
4 countries · 8 shipments
Africa
$478K
35.0% of trade
7 countries · 24 shipments
Fig 4.1 Algeria is the #1 corridor ($390K) — 18 flow arcs from India radiate across 3 continents.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The world map shows every country colored by how much Indian efavirenz it receives (light = low, dark = high). Orange arcs radiate from India to the top 18 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
| # | Destination | Total USD | Ships | #1 Indian supplier | USD | #2 Indian supplier | USD | #3 Indian supplier | USD |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Algeria | $390K | 12 | CIPLA LTD | $270K | MACLEODS PHARMACEUTICALS LTD | $120K | — | — |
| 2 | United States | $231K | 3 | AUROBINDO PHARMA LTD | $231K | — | — | — | — |
| 3 | Vietnam | $230K | 4 | MACLEODS PHARMACEUTICALS LTD | $230K | — | — | — | — |
| 4 | Trinidad and Tobago | $140K | 3 | MACLEODS PHARMACEUTICALS LTD | $140K | — | — | — | — |
| 5 | Myanmar | $117K | 3 | CIPLA LTD | $117K | MICRO LABS LTD | $344 | — | — |
| 6 | Malaysia | $107K | 1 | MYLAN LABORATORIES LTD | $107K | — | — | — | — |
| 7 | Colombia | $56K | 1 | AUROBINDO PHARMA LTD | $56K | — | — | — | — |
| 8 | Tanzania | $44K | 4 | MACLEODS PHARMACEUTICALS LTD | $44K | — | — | — | — |
| 9 | Morocco | $28K | 1 | SUN PHARMACEUTICAL INDUSTRIES LTD | $28K | — | — | — | — |
| 10 | Eritrea | $8K | 1 | MACLEODS PHARMACEUTICALS LTD | $8K | — | — | — | — |
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 33.8% of USD — but Algeria is the single largest market.
Region → country treemap
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
28.5%
#1 country share
Algeria alone
81.0%
Top 5 share
5 of 18 countries
100.0%
Top 15 share
Long tail of 3 countries = 0.0%
HHI 1653
Destination HHI
Moderately concentrated
18
Countries served
Global pharma reach from India
7
Africa countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
10 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAY
MACLEODS PHARMACEUTICALS LTD ($542.4K, 39.6% share) and CIPLA LTD ($392.6K) together control 68.3% of India’s 2025-Q4 efavirenz trade. The top 5 suppliers hold 99.2%. 10 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian efavirenz suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 MACLEODS PHARMACEUTICALS LTD leads by $150K over CIPLA LTD — top 10 Indian exporters ranked by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: DERRIC WOOD is #10 by value but #6 by volume.
Fig 5.2 MACLEODS PHARMACEUTICALS LTD also leads by shipment count (18) but ranking shifts for volume-heavy players
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: DERRIC WOOD moves from #6 by volume to #10 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 10 efavirenz suppliers split into strategic segments
KEY TAKEAWAY
3 suppliers (25%) generate 89.3% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 MACLEODS PHARMACEUTICALS LTD and CIPLA LTD sit in the leaders zone — high volume AND high value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 89.3% of USD — classic concentration.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Top bar = supplier %, bottom bar = USD %. The gap = market concentration.
Product variety — how many formulations each supplier ships
| # | Supplier | Dosage forms | Countries | USD |
|---|---|---|---|---|
| 1 | MACLEODS PHARMACEUTICALS LTD | 2 | 6 | $542K |
| 2 | CIPLA LTD | 2 | 4 | $393K |
| 3 | AUROBINDO PHARMA LTD | 1 | 2 | $287K |
| 4 | MYLAN LABORATORIES LTD | 1 | 2 | $107K |
| 5 | SUN PHARMACEUTICAL INDUSTRIES LTD | 1 | 2 | $28K |
| 6 | GNH INDIA PHARMACEUTICALS LTD | 1 | 1 | $8K |
| 7 | SIDDHIVINAYAK DISTRIBUTORS | 1 | 1 | $2K |
| 8 | H V A INTERNATIONAL | 1 | 1 | $693 |
| 9 | MICRO LABS LTD | 1 | 1 | $344 |
| 10 | DERRIC WOOD | 1 | 1 | $48 |
Table 5.1 — The more dosage forms a supplier ships, the more versatile their manufacturing capability.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — India Origin Geography & Concentration
Which Indian cities and states are the efavirenz manufacturing hubs
KEY TAKEAWAY
Hyderabad and Baddi together account for $666K of India’s 2025-Q4 efavirenz trade.
Fig 5.5 Hyderabad (2 exporters, $394K) and Baddi (1 exporters, $272K) are India’s efavirenz capitals.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Orange bubbles mark major pharma hub cities; bubble size = USD value. Every hub labeled.
§5.1 Supplier concentration metrics
99.2%
Top 5 share
5 of 10 suppliers
100.0%
Top 10 share
10 of 10 suppliers
89.3%
Top 25% share
3 suppliers = 89% USD
HHI 2902
Supplier HHI
Concentrated
10
Total suppliers
shipped Efavirenz in 2025-Q4
13+ cities
Indian hubs
Hyderabad and Baddi lead
§5.2 Coming next: 2 exporter deep-dive profiles
Each of the top 2 suppliers gets a dedicated 2-page profile with:
- 6 KPI cards — trade value, shipments, countries, buyers, avg ship value, branded share
- Dosage form breakdown — what formulations they ship
- Monthly trend — Oct / Nov / Dec trajectory
- Trade flow map — supplier → country → importer connections
- Buyer portfolio with lock-in analysis
SUPPLIER PROFILES IN THIS REPORT
| #1 | MACLEODS PHARMACEUTICALS LTD | $542K |
| #2 | CIPLA LTD | $393K |
#1
EXPORTER PROFILE #1 OF 2
MACLEODS PHARMACEUTICALS LTD
Baddi · India’s #1 efavirenz supplier by USD · 2025-Q4
2025-Q4 USD
$542K
39.6% market share
SHIPMENTS
18
avg $30K/ship
COUNTRIES
6
destination markets
BUYERS
7
6 single-sourced
BRANDED
11%
of shipments
DOSAGE FORMS
2
product types
TOP 6 DESTINATIONS
Vietnam is the #1 market at $230K (42% of trade), followed by Trinidad and Tobago at $140K. 6 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | Vietnam | $230K | 4 | 42.5% |
| 2 | Trinidad and Tobago | $140K | 3 | 25.7% |
| 3 | Algeria | $120K | 4 | 22.2% |
| 4 | Tanzania | $44K | 4 | 8.1% |
| 5 | Eritrea | $8K | 1 | 1.5% |
| 6 | Azerbaijan | $49 | 2 | 0.0% |
MONTHLY TREND
Dec was the strongest month, ending the quarter on a high at $353K.
PRODUCT MIX
Tablet dominates at 74% of trade. Other (25.7%) and Unknown are secondary formulations.
TOP BUYERS · 6/6 LOCKED IN
6 of 6 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| MINISTRY OF HEALTH | Trinidad and Tobago | $184K | ⚠ Locked |
| VIETNAM INTERNATIONAL … | Vietnam | $180K | ⚠ Locked |
| PHARMACIE CENTRALE DES… | Algeria | $120K | ⚠ Locked |
| CENTRAL PHARMACEUTICAL… | Vietnam | $25K | ⚠ Locked |
| Undisclosed buyer | Vietnam | $25K | N/A |
| PROJECT MANAGEMENT UNIT | Eritrea | $8K | ⚠ Locked |
| MINISTRY OF HEALTH OF … | Azerbaijan | $49 | ⚠ Locked |
#1
EXPORTER PROFILE #1 OF 2 — TRADE FLOW MAP
MACLEODS PHARMACEUTICALS LTD — Supplier → Country → Importer
5 destination countries, top 5 importers per country
Fig 5.P1.3 Vietnam absorbs $230K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 3 importers per destination.
#2
EXPORTER PROFILE #2 OF 2
CIPLA LTD
Parel Mumbai Maharashtra · India’s #2 efavirenz supplier by USD · 2025-Q4
2025-Q4 USD
$393K
28.7% market share
SHIPMENTS
15
avg $26K/ship
COUNTRIES
4
destination markets
BUYERS
5
4 single-sourced
BRANDED
100%
of shipments
DOSAGE FORMS
2
product types
TOP 4 DESTINATIONS
Algeria is the #1 market at $270K (69% of trade), followed by Myanmar at $117K. 4 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | Algeria | $270K | 8 | 68.8% |
| 2 | Myanmar | $117K | 2 | 29.7% |
| 3 | Zambia | $5K | 1 | 1.2% |
| 4 | Libya | $1K | 4 | 0.4% |
MONTHLY TREND
Nov peaked at $270K. Oct was the weakest at $0.
PRODUCT MIX
Capsule dominates at 69% of trade. Tablet (31.2%) and others are secondary formulations.
TOP BUYERS · 4/4 LOCKED IN
4 of 4 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| PHARMACIE CENTRALE DES… | Algeria | $135K | ⚠ Locked |
| Undisclosed buyer | Algeria | $135K | N/A |
| JDS CO LTD | Myanmar | $117K | ⚠ Locked |
| KARMA PHARMACEUTICALS … | Zambia | $5K | ⚠ Locked |
| OYA PHARMA | Libya | $1K | ⚠ Locked |
#2
EXPORTER PROFILE #2 OF 2 — TRADE FLOW MAP
CIPLA LTD — Supplier → Country → Importer
4 destination countries, top 5 importers per country
Fig 5.P2.3 Algeria absorbs $270K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 4 destinations and up to 2 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
23 importers across 18 countries — who is buying Indian efavirenz and how much
KEY TAKEAWAY
The demand side is dramatically more fragmented than supply: the top 21 importers together hold only 87.7% of total USD. 96% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian efavirenz. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 AUROBINDO PHARMA USA. INC is the #1 importer at $202K (14.8%) — top 21 by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one global importer ranked by USD.
Fig 6.2 Re-ranked by shipment count — compare with Fig 6.1 for divergences
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same 21 importers re-ranked by shipment count.
§6.1 Sourcing diversity — how many Indian suppliers does each buyer use?
96%
Single-source
22 buyers rely on exactly 1 Indian supplier
4%
Dual-source
1 buyers use 2 Indian suppliers
0%
Multi-source (3–4)
0 buyers diversified across 3–4
0%
Broad-source (5+)
0 buyers with 5+ Indian suppliers
06
PART III — WHO’S IN THIS MARKET
Single-Source Buyers & Price Benchmark
Lock-in opportunities grouped by country + where each buyer sits on the price spectrum
KEY TAKEAWAY
These importers source efavirenz from exactly one Indian supplier. For each one, the table shows the incumbent, price, and dosage.
S FOR SUPPLIERS
This is your target list. Each row is a buyer locked into one competitor. Offer 5–10% better pricing to win the second-source slot.
B FOR BUYERS
If you see your company here, you are fully dependent on one Indian supplier. Consider qualifying a second source.
§6.2 Single-source lock-in by country
United States 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| AUROBINDO PHARMA USA. … | AUROBINDO PHARMA LTD | $202K | $0.439 | Tablet |
| AUROLOGISTICS LLC | AUROBINDO PHARMA LTD | $29K | $0.416 | Tablet |
Vietnam 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| VIETNAM INTERNATIONAL … | MACLEODS PHARMACEUTI… | $180K | $0.121 | Tablet |
| CENTRAL PHARMACEUTICAL… | MACLEODS PHARMACEUTI… | $25K | $0.129 | Tablet |
Algeria 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| PHARMACIE CENTRALE DES… | CIPLA LTD | $135K | $0.375 | Capsule |
| PHARMACIE CENTRALE DES… | MACLEODS PHARMACEUTI… | $120K | $0.389 | Tablet |
Myanmar 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| JDS CO LTD | CIPLA LTD | $117K | $0.881 | Tablet |
| DEPARTMENT OF HEALTH | MICRO LABS LTD | $343.629 | $3.336 | Tablet |
Azerbaijan 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| MINISTRY OF HEALTH OF … | MACLEODS PHARMACEUTI… | $49.326 | $0.0015 | Tablet |
| ZEYTUN PHARMACEUTICALS… | SUN PHARMACEUTICAL I… | $17.473 | $0.0012 | Tablet |
§6.3 Price positioning — top 21 importers
| # | Importer | Country | USD | $/ship | Tier |
|---|---|---|---|---|---|
| 1 | AUROBINDO PHARMA USA… | United States | $202K | $101K | Premium |
| 2 | MINISTRY OF HEALTH | Trinidad and Tobago | $184K | $26K | Mid |
| 3 | VIETNAM INTERNATIONA… | Vietnam | $180K | $90K | Premium |
| 4 | PHARMACIE CENTRALE D… | Algeria | $135K | $34K | Mid |
| 5 | PHARMACIE CENTRALE D… | Algeria | $120K | $30K | Mid |
| 6 | JDS CO LTD | Myanmar | $117K | $58K | Premium |
| 7 | PAHANG PHARMACY SDN … | Malaysia | $107K | $107K | Premium |
| 8 | AUROBINDO PHARMA COL… | Colombia | $56K | $56K | Premium |
| 9 | AUROLOGISTICS LLC | United States | $29K | $29K | Mid |
| 10 | SUN PHARMACEUTICALS … | Morocco | $28K | $28K | Mid |
| 11 | CENTRAL PHARMACEUTIC… | Vietnam | $25K | $25K | Mid |
| 12 | PROJECT MANAGEMENT U… | Eritrea | $8K | $8K | Budget |
| 13 | KARMA PHARMACEUTICAL… | Zambia | $5K | $5K | Budget |
| 14 | SOGUIPREM | Guinea | $2K | $2K | Budget |
| 15 | OYA PHARMA | Libya | $1K | $351.000 | Budget |
| 16 | NEW GPC INC | Guyana | $692.528 | $693.000 | Budget |
| 17 | DEPARTMENT OF HEALTH | Myanmar | $343.629 | $344.000 | Budget |
| 18 | MINISTRY OF HEALTH O… | Azerbaijan | $49.326 | $25.000 | Budget |
| 19 | EMIRATES POST COMPANY | United Arab Emirates | $47.724 | $24.000 | Budget |
| 20 | ATLANTA MEDICARE CO … | Thailand | $37.897 | $38.000 | Budget |
| 21 | ZEYTUN PHARMACEUTICA… | Azerbaijan | $17.473 | $17.000 | Budget |
06
PART III — WHO’S IN THIS MARKET
Market Relationship Map
The top 10 × 20 supplier ↔ buyer network as a circular flow diagram
Fig 6.3 MACLEODS PHARMACEUTICALS LTD → AUROBINDO PHARMA USA. INC is the strongest relationship.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left semicircle = top 10 Indian suppliers; right = top 20 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian efavirenz prices vary by supplier, country and dosage form
KEY TAKEAWAY
Efavirenz prices span 124894× ($0.0002 → $23.95). The coefficient of variation is 2.72. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
§7.1 Price distribution · Table 7.1
| Statistic | Value | Interpretation |
|---|---|---|
| Min | $0.0002 | Lowest observed unit price |
| P5 | $0.0012 | 5th percentile |
| P25 | $0.123 | 25th percentile (Q1) |
| Median | $0.375 | 50th percentile (Q2) |
| P75 | $0.433 | 75th percentile (Q3) |
| P95 | $9.43 | 95th percentile |
| Max | $23.95 | Highest observed unit price |
| Mean | $1.93 | Arithmetic average |
| CV | 272% | Coefficient of variation (std/mean) |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 7.1 DERRIC WOOD prices at $23.86/unit vs market median $0.375.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. MACLEODS PHARMACEUTICALS LTD Sourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. DERRIC WOOD Sourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. Sourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. e.g. GNH INDIA PHARMACEUTICALS Sourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAY
Extreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Nov 2025 | DERRIC WOOD | United Arab Emirates | Tablet | 1 | $23.95 | $23.95 | Specialty / small-batch |
| Nov 2025 | DERRIC WOOD | United Arab Emirates | Tablet | 1 | $23.78 | $23.78 | Specialty / small-batch |
| Nov 2025 | GNH INDIA PHARMA… | Singapore | Tablet | 832 | $8K | $9.60 | Specialty / small-batch |
| Dec 2025 | SIDDHIVINAYAK DI… | Guinea | Tablet | 280 | $2K | $6.17 | Specialty / small-batch |
| Dec 2025 | H V A INTERNATIO… | Guyana | Tablet | 140 | $692.53 | $4.95 | Specialty / small-batch |
| Nov 2025 | MICRO LABS LTD | Myanmar | Tablet | 103 | $343.63 | $3.34 | Specialty / small-batch |
| Dec 2025 | CIPLA LTD | Myanmar | Tablet | 113K | $100K | $0.881 | |
| Dec 2025 | CIPLA LTD | Myanmar | Tablet | 19K | $17K | $0.881 | |
| Dec 2025 | CIPLA LTD | Zambia | Tablet | 11K | $5K | $0.440 | |
| Dec 2025 | AUROBINDO PHARMA… | United States | Tablet | 230K | $101K | $0.439 |
↓ TOP 10 LOWEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Dec 2025 | SUN PHARMACEUTIC… | Azerbaijan | Tablet | 15K | $17.47 | $0.0012 | Bulk generic tablet |
| Dec 2025 | MACLEODS PHARMAC… | Azerbaijan | Tablet | 33K | $49.33 | $0.0015 | Bulk generic tablet |
| Dec 2025 | CIPLA LTD | Libya | Tablet | 435K | $904.76 | $0.0021 | Bulk generic tablet |
| Dec 2025 | CIPLA LTD | Libya | Tablet | 239K | $497.32 | $0.0021 | Bulk generic tablet |
| Dec 2025 | SUN PHARMACEUTIC… | Morocco | Tablet | 362K | $28K | $0.078 | |
| Dec 2025 | AUROBINDO PHARMA… | Colombia | Tablet | 659K | $56K | $0.085 | |
| Dec 2025 | MACLEODS PHARMAC… | Eritrea | Tablet | 73K | $8K | $0.110 | |
| Dec 2025 | MACLEODS PHARMAC… | Vietnam | Tablet | 792K | $96K | $0.121 | |
| Dec 2025 | MACLEODS PHARMAC… | Vietnam | Tablet | 691K | $84K | $0.121 | |
| Nov 2025 | MACLEODS PHARMAC… | Vietnam | Tablet | 195K | $25K | $0.129 |
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
- Budget buyer: anchor − 10–15% (floor = cost + freight)
- Mid-market: anchor ± 5–10%
- Premium/tender: anchor + 10–25% (regulated, quality premium)
- Injection/infusion: always 4–10× the tablet price
KEY TAKEAWAYS
- Dosage form is the #1 price driver, not destination
- Light cells = easy-entry markets for small suppliers
- Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship efavirenz, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAY
Efavirenz leaves India through 6+ ports. The top 5 (DELHI AIR, MUMBAI AIR (SAHAR), HYDERABAD ICD) handle 100.0% of total USD. AIR moves 85% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 DELHI AIR handles $533K — top 6 Indian origin ports by trade value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian port. Bar length = USD value. The largest ports handle the majority of trade.
Fig 8.2 ALGIERS is the #1 global destination port — top 22 by USD value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
| Route | Mode | Transit time | Notes |
|---|---|---|---|
| NHAVA SHEVA SEA (JNPT) → US East Coast | Sea | 22–28 days | Via Suez; 2–3 transshipments typical |
| NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria) | Sea | 18–24 days | Direct liner service available |
| MUMBAI AIR (SAHAR) → New York JFK | Air | 3–5 days | Direct cargo; cold-chain available |
| MUNDRA SEA → Rotterdam | Sea | 20–26 days | Via Suez; Hamburg also served |
| HYDERABAD AIR → London Heathrow | Air | 2–4 days | Pharma-grade cargo corridor |
| CHENNAI SEA → Chittagong (Bangladesh) | Sea | 7–12 days | Short-sea route; high frequency |
| RAXAUL → Birgunj (Nepal) | Road | 1–2 days | Land border crossing |
| NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya) | Sea | 14–20 days | Direct or via Colombo hub |
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAY
AIR dominates at 85% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
AIR
$958K
70.1% of USD · 85.1% of ships
ICD
$298K
21.8% of USD · 10.6% of ships
SEA
$111K
8.1% of USD · 4.3% of ships
Fig 8.3 The dominant corridor is MUMBAI AIR (SAHAR) → Air → Africa ($271K).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAY
Vietnam is the most concentrated destination (HHI 10000, 1 suppliers). Algeria is the most competitive (HHI 5737).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Vietnam (HHI 10,000) is the most concentrated — Algeria (HHI 5,737) is the most competitive.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 18 of 18 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
| Buyer | Country | Sole supplier | USD | Ships | Risk |
|---|---|---|---|---|---|
| AUROBINDO PHARMA USA… | United States | AUROBINDO PHARMA… | $202K | 2 | HIGH |
| MINISTRY OF HEALTH | Trinidad and Tobago | MACLEODS PHARMAC… | $184K | 7 | HIGH |
| VIETNAM INTERNATIONA… | Vietnam | MACLEODS PHARMAC… | $180K | 2 | HIGH |
| PHARMACIE CENTRALE D… | Algeria | CIPLA LTD | $135K | 4 | HIGH |
| PHARMACIE CENTRALE D… | Algeria | MACLEODS PHARMAC… | $120K | 4 | HIGH |
| JDS CO LTD | Myanmar | CIPLA LTD | $117K | 2 | HIGH |
| PAHANG PHARMACY SDN … | Malaysia | MYLAN LABORATORI… | $107K | 1 | HIGH |
| AUROBINDO PHARMA COL… | Colombia | AUROBINDO PHARMA… | $56K | 1 | MEDIUM |
Conclusion: 21 buyers depend on exactly one Indian supplier, representing $1.2M in trade. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
| Buyer | Country | Suppliers | USD | Dominant | Resilience |
|---|
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY
15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
| Country | Tier | Lead | Price | Risk | Entry approach |
|---|---|---|---|---|---|
| Algeria | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
| United States | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
| Vietnam | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
| Trinidad and Tobago | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
| Myanmar | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Malaysia | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Colombia | Tier 3 (emerging) | 14–28 days (sea) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Tanzania | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Morocco | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Eritrea | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
| Singapore | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Zambia | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Guinea | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Libya | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Guyana | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 15 in Fragile Dependency (concentrated + shrinking).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 15 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAY
Quick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 15 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A1 | Pitch top single-source buyer in United States | This Q | HIGH |
| A2 | Offer alternative to top multi-source buyer | This Q | HIGH |
| A3 | Audit Vietnam lock-ins (HHI 10000) | This Q | MED |
| A5 | Enter Algeria (2 suppliers) | This Q | HIGH |
| A6 | Enter United States (1 suppliers) | This Q | MED |
| A8 | Build United States distribution | 6–12m | HIGH |
| A9 | Bundle injection/infusion catalog for premium markets | 6–12m | MED |
B
FOR BUYERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A4 | Monitor rising exporters (climbers) | This Q | MED |
| A7 | Register for Algeria tenders | 6–12m | HIGH |
| A10 | Track quarterly HHI shifts across key destinations | This Q | LOW |
| A11 | Map competitor buyer portfolios quarterly | This Q | MED |
| A12 | Qualify second source for single-source buyers | This Q | MED |
§9.4 Easy-entry markets — 15 countries with ≤5 Indian suppliers
| # | Country | Region | Suppliers | Q4 USD | Growth | Barrier | Why this is easy |
|---|---|---|---|---|---|---|---|
| 1 | Algeria | Africa | 2 | $390K | 0% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 2 | United States | Other | 1 | $231K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 3 | Vietnam | Asia | 1 | $230K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 4 | Trinidad and Tobago | Other | 1 | $140K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 5 | Myanmar | Asia | 2 | $117K | 0% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 6 | Malaysia | Asia | 1 | $107K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 7 | Colombia | Other | 1 | $56K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 8 | Tanzania | Africa | 1 | $44K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 9 | Morocco | Africa | 1 | $28K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 10 | Eritrea | Africa | 1 | $8K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 11 | Singapore | Asia | 1 | $8K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 12 | Zambia | Africa | 1 | $5K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 13 | Guinea | Africa | 1 | $2K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 14 | Libya | Africa | 1 | $1K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 15 | Guyana | Other | 1 | $693 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
This report covers 47 2025-Q4 Efavirenz shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/efavirenz
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAY
This section contains every one of the 47 2025-Q4 efavirenz shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian efavirenz shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
47
across all regions
TOTAL USD
$1.37M
2025-Q4 FOB value
UNITS
8.1M
tablets, capsules, etc.
SUPPLIERS
10
Indian exporters
BUYERS
23
global importers
COUNTRIES
18
destinations
§10.2 Regional breakdown
§10.3 Key insights from the data
Africa is the largest region at $478K (35.0%), spanning 7 countries.
10 Indian suppliers shipped to 23 buyers across 18 countries — average shipment value $29K.
Top 0 markets: .
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
§10.4 How to read a country page
1
6 KPI cards — shipments, USD, qty, exporters, importers, avg unit price.
2
4 mini-lists — top exporters, importers, dosages, monthly trend.
3
Shipment register — every row grouped by exporter. No row is duplicated or omitted.
10
PART VI — DRILL-DOWN · AFRICA
Region: Africa
7 countries · 24 shipments · $478K · 4 Indian suppliers · 9 buyers
SHIPMENTS
24
USD
$478K
COUNTRIES
7
SUPPLIERS
4
BUYERS
9
HHI
4,663
concentrated
Top 7 destination countries in Africa
1
Algeria (81.6%)
$390K
2
Tanzania (9.2%)
$44K
3
Morocco (5.9%)
$28K
4
Eritrea (1.7%)
$8K
5
Zambia (1.0%)
$5K
6
Guinea (0.4%)
$2K
7
Libya (0.3%)
$1K
Top 4 Indian suppliers into Africa
1
CIPLA LTD
$276K
2
MACLEODS PHARMACEUTICALS LTD
$172K
3
SUN PHARMACEUTICAL INDUSTRIES LTD
$28K
4
SIDDHIVINAYAK DISTRIBUTORS
$2K
Top 8 Africa importers
1
PHARMACIE CENTRALE DES HOPITAUX PCH · Algeria
$135K
2
PHARMACIE CENTRALE DES HOPITAUX · Algeria
$120K
3
MINISTRY OF HEALTH · Tanzania
$44K
4
SUN PHARMACEUTICALS MOROCCO LLC · Morocco
$28K
5
PROJECT MANAGEMENT UNIT · Eritrea
$8K
6
KARMA PHARMACEUTICALS LTD · Zambia
$5K
7
SOGUIPREM · Guinea
$2K
8
OYA PHARMA · Libya
$1K
Top 3 dosage forms
1
Capsule
$270K
2
Tablet
$208K
3
Unknown
$0.0000
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 8 | $270K | $34K |
| Dec | 16 | $208K | $13K |
Shipment register · 24 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — CIPLA LTD · 13 shipments · $276K | |||||||||||
| 1 | Nov 2025 | PHARMACIE CENTRALE DES HOPITAUX PCH | Algeria | Capsule | 92.7K | NOS | $0.375 | $35K | MUMBAI AIR (SAHAR) | ALGIERS | AIR |
| 2 | Nov 2025 | PHARMACIE CENTRALE DES HOPITAUX PCH | Algeria | Capsule | 90.7K | NOS | $0.375 | $34K | MUMBAI AIR (SAHAR) | ALGIERS | AIR |
| 3 | Nov 2025 | PHARMACIE CENTRALE DES HOPITAUX PCH | Algeria | Capsule | 89.2K | NOS | $0.375 | $33K | MUMBAI AIR (SAHAR) | ALGIERS | AIR |
| 4 | Nov 2025 | PHARMACIE CENTRALE DES HOPITAUX PCH | Algeria | Capsule | 87.2K | NOS | $0.375 | $33K | MUMBAI AIR (SAHAR) | ALGIERS | AIR |
| 5 | Nov 2025 | UNKNOWN BUYER | Algeria | Capsule | 92.7K | NOS | $0.375 | $35K | MUMBAI AIR (SAHAR) | ALGIERS | AIR |
| 6 | Nov 2025 | UNKNOWN BUYER | Algeria | Capsule | 90.7K | NOS | $0.375 | $34K | MUMBAI AIR (SAHAR) | ALGIERS | AIR |
| 7 | Nov 2025 | UNKNOWN BUYER | Algeria | Capsule | 89.2K | NOS | $0.375 | $33K | MUMBAI AIR (SAHAR) | ALGIERS | AIR |
| 8 | Nov 2025 | UNKNOWN BUYER | Algeria | Capsule | 87.2K | NOS | $0.375 | $33K | MUMBAI AIR (SAHAR) | ALGIERS | AIR |
| 9 | Dec 2025 | OYA PHARMA | Libya | Tablet | 436.7K | NOS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | TRIPOLI | AIR |
| 10 | Dec 2025 | OYA PHARMA | Libya | Tablet | 239.0K | NOS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | TRIPOLI | AIR |
| 11 | Dec 2025 | OYA PHARMA | Libya | Tablet | 434.9K | NOS | $0.0021 | $904.76 | MUMBAI AIR (SAHAR) | TRIPOLI | AIR |
| 12 | Dec 2025 | OYA PHARMA | Libya | Tablet | 239.0K | NOS | $0.0021 | $497.32 | MUMBAI AIR (SAHAR) | TRIPOLI | AIR |
| 13 | Dec 2025 | KARMA PHARMACEUTICALS LTD | Zambia | Tablet | 10.5K | NOS | $0.440 | $5K | NHAVA SHEVA SEA (JNPT) | Lusaka | SEA |
| SUPPLIER #2 — MACLEODS PHARMACEUTICALS LTD · 9 shipments · $172K | |||||||||||
| 14 | Dec 2025 | MINISTRY OF HEALTH | Tanzania | Tablet | 32.0K | NOS | $0.131 | $4K | DELHI AIR | DAR ES SALAM (DARESS | AIR |
| 15 | Dec 2025 | MINISTRY OF HEALTH | Tanzania | 1 | NOS | $0.0000 | $0.0000 | DELHI AIR | DAR ES SALAM (DARESS | AIR | |
| 16 | Dec 2025 | PHARMACIE CENTRALE DES HOPITAUX | Algeria | Tablet | 162.0K | NOS | $0.385 | $62K | DELHI AIR | ALGIERS | AIR |
| 17 | Dec 2025 | PHARMACIE CENTRALE DES HOPITAUX | Algeria | Tablet | 60 | NOS | $0.0002 | $0.013 | DELHI AIR | ALGIERS | AIR |
| 18 | Dec 2025 | PROJECT MANAGEMENT UNIT | Eritrea | Tablet | 73.2K | NOS | $0.110 | $8K | DELHI AIR | ASMARA | AIR |
| 19 | Dec 2025 | MINISTRY OF HEALTH | Tanzania | Tablet | 306.0K | NOS | $0.130 | $40K | STARTRACK TERMINAL ICD | DAR ES SALAAM | ICD |
| 20 | Dec 2025 | MINISTRY OF HEALTH | Tanzania | 1 | NOS | $0.0000 | $0.0000 | STARTRACK TERMINAL ICD | DAR ES SALAAM | ICD | |
| 21 | Dec 2025 | PHARMACIE CENTRALE DES HOPITAUX | Algeria | Tablet | 147.0K | NOS | $0.393 | $58K | DELHI AIR | ALGIERS | AIR |
| 22 | Dec 2025 | PHARMACIE CENTRALE DES HOPITAUX | Algeria | Tablet | 60 | NOS | $0.0002 | $0.012 | DELHI AIR | ALGIERS | AIR |
| SUPPLIER #3 — SUN PHARMACEUTICAL INDUSTRIES LTD · 1 shipments · $28K | |||||||||||
| 23 | Dec 2025 | SUN PHARMACEUTICALS MOROCCO LLC | Morocco | Tablet | 361.8K | NOS | $0.078 | $28K | DELHI AIR | CASABLANCA | AIR |
| SUPPLIER #4 — SIDDHIVINAYAK DISTRIBUTORS · 1 shipments · $2K | |||||||||||
| 24 | Dec 2025 | SOGUIPREM | Guinea | Tablet | 280 | NOS | $6.17 | $2K | DELHI AIR | CONAKRY | AIR |
10
PART VI — DRILL-DOWN · ASIA
Region: Asia
7 countries · 15 shipments · $462K · 7 Indian suppliers · 11 buyers
SHIPMENTS
15
USD
$462K
COUNTRIES
7
SUPPLIERS
7
BUYERS
11
HHI
3,660
concentrated
Top 7 destination countries in Asia
1
Vietnam (49.9%)
$230K
2
Myanmar (25.3%)
$117K
3
Malaysia (23.1%)
$107K
4
Singapore (1.7%)
$8K
5
Azerbaijan (0.0%)
$66.80
6
United Arab Emirates (0.0%)
$47.72
7
Thailand (0.0%)
$37.90
Top 7 Indian suppliers into Asia
1
MACLEODS PHARMACEUTICALS LTD
$230K
2
CIPLA LTD
$117K
3
MYLAN LABORATORIES LTD
$107K
4
GNH INDIA PHARMACEUTICALS LTD
$8K
5
MICRO LABS LTD
$343.63
6
DERRIC WOOD
$47.72
7
SUN PHARMACEUTICAL INDUSTRIES LTD
$17.47
Top 9 Asia importers
1
VIETNAM INTERNATIONAL COMMERCIAL · Vietnam
$180K
2
JDS CO LTD · Myanmar
$117K
3
PAHANG PHARMACY SDN BHD · Malaysia
$107K
4
CENTRAL PHARMACEUTICAL CPC · Vietnam
$25K
5
DEPARTMENT OF HEALTH · Myanmar
$343.63
6
MINISTRY OF HEALTH OF THE · Azerbaijan
$49.33
7
EMIRATES POST COMPANY · United Arab Emirates
$47.72
8
ATLANTA MEDICARE CO LTD · Thailand
$37.90
9
ZEYTUN PHARMACEUTICALS LLC · Azerbaijan
$17.47
Top 1 dosage forms
1
Tablet
$462K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 1 | $107K | $107K |
| Nov | 6 | $59K | $10K |
| Dec | 8 | $297K | $37K |
Shipment register · 15 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — MACLEODS PHARMACEUTICALS LTD · 6 shipments · $230K | |||||||||||
| 1 | Nov 2025 | CENTRAL PHARMACEUTICAL CPC | Vietnam | Tablet | 195.0K | NOS | $0.129 | $25K | DELHI AIR | HANOI - NOIBAI | AIR |
| 2 | Nov 2025 | UNKNOWN BUYER | Vietnam | Tablet | 195.0K | NOS | $0.129 | $25K | DELHI AIR | HANOI - NOIBAI | AIR |
| 3 | Dec 2025 | MINISTRY OF HEALTH OF THE | Azerbaijan | Tablet | 1 | NOS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | BAKU | AIR |
| 4 | Dec 2025 | MINISTRY OF HEALTH OF THE | Azerbaijan | Tablet | 33.1K | NOS | $0.0015 | $49.33 | MUMBAI AIR (SAHAR) | BAKU | AIR |
| 5 | Dec 2025 | VIETNAM INTERNATIONAL COMMERCIAL | Vietnam | Tablet | 691.3K | NOS | $0.121 | $84K | DELHI AIR | HO CHI MINH C | AIR |
| 6 | Dec 2025 | VIETNAM INTERNATIONAL COMMERCIAL | Vietnam | Tablet | 791.8K | NOS | $0.121 | $96K | DELHI AIR | HO CHI MINH C | AIR |
| SUPPLIER #2 — CIPLA LTD · 2 shipments · $117K | |||||||||||
| 7 | Dec 2025 | JDS CO LTD | Myanmar | Tablet | 18.9K | NOS | $0.881 | $17K | MUMBAI AIR (SAHAR) | YANGON | AIR |
| 8 | Dec 2025 | JDS CO LTD | Myanmar | Tablet | 113.4K | NOS | $0.881 | $100K | MUMBAI AIR (SAHAR) | YANGON | AIR |
| SUPPLIER #3 — MYLAN LABORATORIES LTD · 2 shipments · $107K | |||||||||||
| 9 | Oct 2025 | PAHANG PHARMACY SDN BHD | Malaysia | Tablet | 709.1K | NOS | $0.150 | $107K | NHAVA SHEVA SEA (JNPT) | Port Kelang | SEA |
| 10 | Dec 2025 | ATLANTA MEDICARE CO LTD | Thailand | Tablet | 150 | NOS | $0.253 | $37.90 | MUMBAI AIR (SAHAR) | BANGKOK | AIR |
| SUPPLIER #4 — GNH INDIA PHARMACEUTICALS LTD · 1 shipments · $8K | |||||||||||
| 11 | Nov 2025 | UNLISTED BUYER | Singapore | Tablet | 832 | NOS | $9.60 | $8K | MUMBAI AIR (SAHAR) | SINGAPORE | AIR |
| SUPPLIER #5 — MICRO LABS LTD · 1 shipments · $343.63 | |||||||||||
| 12 | Nov 2025 | DEPARTMENT OF HEALTH | Myanmar | Tablet | 103 | PCS | $3.34 | $343.63 | BANGALORE AIR | YANGON | AIR |
| SUPPLIER #6 — DERRIC WOOD · 2 shipments · $47.72 | |||||||||||
| 13 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 1 | PCS | $23.78 | $23.78 | DELHI AIR | DUBAI | AIR |
| 14 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 1 | PCS | $23.95 | $23.95 | DELHI AIR | DUBAI | AIR |
| SUPPLIER #7 — SUN PHARMACEUTICAL INDUSTRIES LTD · 1 shipments · $17.47 | |||||||||||
| 15 | Dec 2025 | ZEYTUN PHARMACEUTICALS LLC | Azerbaijan | Tablet | 15.0K | NOS | $0.0012 | $17.47 | DELHI AIR | BAKU | AIR |
10
PART VI — DRILL-DOWN · AMERICAS
Region: Americas
4 countries · 8 shipments · $428K · 3 Indian suppliers · 5 buyers
SHIPMENTS
8
USD
$428K
COUNTRIES
4
SUPPLIERS
3
BUYERS
5
HHI
5,580
concentrated
Top 4 destination countries in Americas
1
United States (54.0%)
$231K
2
Trinidad and Tobago (32.7%)
$140K
3
Colombia (13.1%)
$56K
4
Guyana (0.2%)
$692.53
Top 3 Indian suppliers into Americas
1
AUROBINDO PHARMA LTD
$287K
2
MACLEODS PHARMACEUTICALS LTD
$140K
3
H V A INTERNATIONAL
$692.53
Top 5 Americas importers
1
AUROBINDO PHARMA USA. INC · United States
$202K
2
MINISTRY OF HEALTH · Trinidad and Tobago
$140K
3
AUROBINDO PHARMA COLOMBIA SAS · Colombia
$56K
4
AUROLOGISTICS LLC · United States
$29K
5
NEW GPC INC · Guyana
$692.53
Top 2 dosage forms
1
Tablet
$288K
2
Other
$140K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 3 | $140K | $47K |
| Dec | 5 | $288K | $58K |
Shipment register · 8 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — AUROBINDO PHARMA LTD · 4 shipments · $287K | |||||||||||
| 1 | Dec 2025 | AUROBINDO PHARMA USA. INC | United States | Tablet | 230.4K | NOS | $0.439 | $101K | HYDERABAD ICD | NEWARK | ICD |
| 2 | Dec 2025 | AUROBINDO PHARMA USA. INC | United States | Tablet | 230.4K | NOS | $0.439 | $101K | HYDERABAD ICD | Newark | ICD |
| 3 | Dec 2025 | AUROLOGISTICS LLC | United States | Tablet | 69.1K | NOS | $0.416 | $29K | MUMBAI AIR (SAHAR) | NEW YORK | AIR |
| 4 | Dec 2025 | AUROBINDO PHARMA COLOMBIA SAS | Colombia | Tablet | 658.8K | NOS | $0.085 | $56K | HYDERABAD ICD | BUENAVENTURA | ICD |
| SUPPLIER #2 — MACLEODS PHARMACEUTICALS LTD · 3 shipments · $140K | |||||||||||
| 5 | Nov 2025 | MINISTRY OF HEALTH | Trinidad and Tobago | Other | 666.3K | NOS | $0.140 | $93K | DELHI AIR | PORT OF SPAIN, PIARC | AIR |
| 6 | Nov 2025 | MINISTRY OF HEALTH | Trinidad and Tobago | Other | 195.2K | NOS | $0.140 | $27K | DELHI AIR | PORT OF SPAIN, PIARC | AIR |
| 7 | Nov 2025 | MINISTRY OF HEALTH | Trinidad and Tobago | Other | 138.5K | NOS | $0.140 | $19K | DELHI AIR | PORT OF SPAIN, PIARC | AIR |
| SUPPLIER #3 — H V A INTERNATIONAL · 1 shipments · $692.53 | |||||||||||
| 8 | Dec 2025 | NEW GPC INC | Guyana | Tablet | 140 | NOS | $4.95 | $692.53 | MUMBAI AIR (SAHAR) | GEORGETOWN | AIR |
10
PART VI — EVIDENCE REGISTER
Indian Supplier Directory
All 10 Indian efavirenz exporters — complete list ranked by USD
KEY TAKEAWAY
This directory lists every Indian company that shipped efavirenz in 2025-Q4.
S FOR SUPPLIERS
Find yourself and your competitors. Compare shipment count, USD, and destination regions.
B FOR BUYERS
Search for potential Indian suppliers. Filter by dosage form and destination region.
| # | Supplier | City | Ships | USD | Dosage forms | Primary regions |
|---|---|---|---|---|---|---|
| 1 | MACLEODS PHARMACEUTICALS LTD | BADDI | 18 | $542K | Tablet, Other | Asia, Americas |
| 2 | CIPLA LTD | PAREL MUMBAI MAHARASHTRA | 15 | $393K | Capsule, Tablet | Africa, Asia |
| 3 | AUROBINDO PHARMA LTD | HYDERABAD | 4 | $287K | Tablet | Americas |
| 4 | MYLAN LABORATORIES LTD | HYDERABAD | 2 | $107K | Tablet | Asia |
| 5 | SUN PHARMACEUTICAL INDUSTRIES LTD | MUMBAI | 2 | $28K | Tablet | Africa, Asia |
| 6 | GNH INDIA PHARMACEUTICALS LTD | MUMBAI | 1 | $8K | Tablet | Asia |
| 7 | SIDDHIVINAYAK DISTRIBUTORS | VARANASI | 1 | $2K | Tablet | Africa |
| 8 | H V A INTERNATIONAL | VILE PARLE EAST | 1 | $692.53 | Tablet | Americas |
| 9 | MICRO LABS LTD | VERNA | 1 | $343.63 | Tablet | Asia |
| 10 | DERRIC WOOD | SUBHASH PLACE | 2 | $47.72 | Tablet | Asia |
10
PART VI — EVIDENCE REGISTER
Global Buyer Directory
All 21 global efavirenz importers — complete list ranked by USD
KEY TAKEAWAY
This directory lists every company that imported Indian efavirenz in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
| # | Buyer | Country | Ships | USD | Primary supplier | Dosage forms |
|---|---|---|---|---|---|---|
| 1 | AUROBINDO PHARMA USA. INC | United States | 2 | $202K | AUROBINDO PHARMA LTD | Tablet |
| 2 | MINISTRY OF HEALTH | Trinidad and Tobago | 7 | $184K | MACLEODS PHARMACEUTI… | Other, Tablet |
| 3 | VIETNAM INTERNATIONAL COMMERCIAL | Vietnam | 2 | $180K | MACLEODS PHARMACEUTI… | Tablet |
| 4 | PHARMACIE CENTRALE DES HOPITAUX PCH | Algeria | 4 | $135K | CIPLA LTD | Capsule |
| 5 | PHARMACIE CENTRALE DES HOPITAUX | Algeria | 4 | $120K | MACLEODS PHARMACEUTI… | Tablet |
| 6 | JDS CO LTD | Myanmar | 2 | $117K | CIPLA LTD | Tablet |
| 7 | PAHANG PHARMACY SDN BHD | Malaysia | 1 | $107K | MYLAN LABORATORIES LTD | Tablet |
| 8 | AUROBINDO PHARMA COLOMBIA SAS | Colombia | 1 | $56K | AUROBINDO PHARMA LTD | Tablet |
| 9 | AUROLOGISTICS LLC | United States | 1 | $29K | AUROBINDO PHARMA LTD | Tablet |
| 10 | SUN PHARMACEUTICALS MOROCCO LLC | Morocco | 1 | $28K | SUN PHARMACEUTICAL I… | Tablet |
| 11 | CENTRAL PHARMACEUTICAL CPC | Vietnam | 1 | $25K | MACLEODS PHARMACEUTI… | Tablet |
| 12 | PROJECT MANAGEMENT UNIT | Eritrea | 1 | $8K | MACLEODS PHARMACEUTI… | Tablet |
| 13 | KARMA PHARMACEUTICALS LTD | Zambia | 1 | $5K | CIPLA LTD | Tablet |
| 14 | SOGUIPREM | Guinea | 1 | $2K | SIDDHIVINAYAK DISTRI… | Tablet |
| 15 | OYA PHARMA | Libya | 4 | $1K | CIPLA LTD | Tablet |
| 16 | NEW GPC INC | Guyana | 1 | $692.53 | H V A INTERNATIONAL | Tablet |
| 17 | DEPARTMENT OF HEALTH | Myanmar | 1 | $343.63 | MICRO LABS LTD | Tablet |
| 18 | MINISTRY OF HEALTH OF THE | Azerbaijan | 2 | $49.33 | MACLEODS PHARMACEUTI… | Tablet |
| 19 | EMIRATES POST COMPANY | United Arab Emirates | 2 | $47.72 | DERRIC WOOD | Tablet |
| 20 | ATLANTA MEDICARE CO LTD | Thailand | 1 | $37.90 | MYLAN LABORATORIES LTD | Tablet |
| 21 | ZEYTUN PHARMACEUTICALS LLC | Azerbaijan | 1 | $17.47 | SUN PHARMACEUTICAL I… | Tablet |
This report covers 47 2025-Q4 Efavirenz shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/efavirenz
Talk to our trade analyst
Need a custom efavirenz report or a deeper dive into any market? Our team is ready.
WhatsApp: +91 95950 78788 · transdatanexus.com
PHARMA TRADE INTELLIGENCE
Thank you for reading
This report is part of the TransData Nexus Pharma Trade Intelligence series, covering 366 pharmaceutical products exported from India.
Every figure is grounded in real commercial trade records — official customs filings and licensed databases. No surveys, no estimates, no fake data.
Need a custom report?
We can generate intelligence for any pharmaceutical product, any time period, any combination of source and destination countries.
Want deeper analysis?
Our team provides competitive intelligence, market entry strategy, and supply chain due diligence for pharma importers and exporters.
Scan for product page
WhatsApp: +91 95950 78788
Email: info@transdatanexus.com
Web: https://transdatanexus.com/pharmaceutical/efavirenz
© 2026 TransData Nexus. All rights reserved. This report is provided for informational purposes only.
Data sourced from official customs filings and licensed commercial trade databases.
Reproduction without permission is prohibited.
Explore the full Efavirenz product page
Live data, supplier directory, price trends, and trade route analysis